Business

Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership

Not for distribution to United States newswire services or for dissemination in the United St...

articleHydreight Technologies IncSeptember 2, 20255/company/hydreight-technologies-inc/news/hydreight-technologies-signs-definitive-agreement-to-acquire-5percent-equity-stake-in-perfect-scripts-llc-with-option-to-increase-to-40percent-and-establish-strategic-partnership
Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership

About this update from Hydreight Technologies Inc

[{"type":"text","content":"Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership\n\n\n\n\n Not for distribution to United States newswire services or for\n \n\n dissemination in the United States.\n \n\n\n VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) --\n \n Hydreight Technologies Inc.\n \n (TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), (\"\n \n Hydreight\n \n \" or the \"\n \n Company\n \n \"), a North American, fully integrated, mobile clinical network of nurses, doctors, and pharmacy distribution, is pleased to announce that, further to its news release dated July 14, 2025, it has entered into binding definitive agreements (collectively, the “\n \n Definitive Agreement\n \n ”) dated September 1, 2025 with Perfect Scripts LLC (“\n \n Perfect Scripts\n \n ”), an arm’s length limited liability company based in Texas, in respect of a strategic partnership. The Definitive Agreement replaces and supersedes the binding letter of intent between the parties dated July 11, 2025.\n \n\n Pursuant to the Definitive Agreement, the parties have agreed that, among other things: (a) Hydreight will acquire an initial 5% membership interest in Perfect Scripts in consideration for 2,250,000 common shares in the capital of Hydreight (the “\n \n Hydreight Compensation Shares\n \n ”), with each Hydreight Compensation Share issued at a deemed price equal to the greater of CAD$2.30 per share and the lowest price permitted by the policies of TSX Venture Exchange (the “\n \n Exchange\n \n ”), (b) Hydreight and Perfect Scripts will partner to start a 503B pharmacy in the United States, (c) Hydreight will receive the lowest pricing for all products sold or made available by Perfect Scripts or its subsidiaries, and (d) Hydreight will be granted a right to (i) maintain its pro rata interest in the outstanding membership interests of Perfect Scripts, and (ii) acquire up to an aggregate 40% interest in the outstanding membership interests of Perfect Scripts, subject to certain conditions (collectively, the “\n \n Transaction\n \n ”).\n \n\n The Company will pay a cash finder’s fee of $258,750, representing 5% of the deemed value of the Transaction, to ...

More updates from Hydreight Technologies Inc